Merck & Co., Inc. $MRK Stock: Birch Hill Investment Advisors LLC Cuts Holdings

Key Points

• Birch Hill Investment Advisors cut its Merck stake by 9.1% in the third quarter, selling 8,040 shares and retaining 79,932 shares valued at approximately $11.6 million. Institutional investors overall own 76.07% of Merck.
• Wall Street remains broadly positive, with 17 analysts rating MRK a Buy and 10 assigning a Hold; the stock has a “Moderate Buy” consensus and an average price target of $151.92.
• Merck faces a mixed outlook: promising Keytruda oncology results and pipeline updates support growth, while Gardasil challenges, insider selling, and a high valuation following a strong 2026 rally could limit further upside.

Birch Hill Investment Advisors LLC lowered its holdings in Merck & Co., Inc. (NYSE:MRK - Free Report) by 9.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 79,932 shares of the company's stock after selling 8,040 shares during the period. Birch Hill Investment Advisors LLC's holdings in Merck & Co., Inc. were worth $11,615,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. BlackRock Inc. raised its stake in Merck & Co., Inc. by 0.5% during the second quarter. BlackRock Inc. now owns 226,999,837 shares of the company's stock valued at $29,169,479,000 after buying an additional 1,073,507 shares in the last quarter. State Street Corp increased its position in shares of Merck & Co., Inc. by 0.9% in the second quarter. State Street Corp now owns 120,413,256 shares of the company's stock worth $15,573,754,000 after acquiring an additional 1,087,583 shares in the last quarter. Wellington Management Group LLP lifted its stake in Merck & Co., Inc. by 2.3% in the 2nd quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company's stock worth $11,083,033,000 after acquiring an additional 1,934,312 shares in the last quarter. Bank of America Corp DE increased its stake in Merck & Co., Inc. by 10.5% in the 1st quarter. Bank of America Corp DE now owns 30,774,221 shares of the company's stock valued at $3,701,831,000 after buying an additional 2,919,780 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in shares of Merck & Co., Inc. by 23.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 15,456,039 shares of the company's stock valued at $1,858,938,000 after buying an additional 2,969,856 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on MRK. Rothschild & Co Redburn raised their target price on Merck & Co., Inc. from $140.00 to $145.00 and gave the company a "buy" rating in a report on Monday, July 6th. Bank of America raised their target price on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the company a "buy" rating in a research note on Tuesday, June 30th. Jefferies Financial Group upped their price objective on shares of Merck & Co., Inc. from $152.00 to $175.00 and gave the company a "buy" rating in a research report on Thursday, August 20th. Cantor Fitzgerald upped their price objective on Merck & Co., Inc. from $120.00 to $145.00 and gave the stock a "neutral" rating in a research report on Thursday, October 8th. Finally, BMO Capital Markets lifted their price target on Merck & Co., Inc. from $142.00 to $170.00 and gave the stock an "outperform" rating in a report on Thursday, August 20th. Seventeen investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat.com, Merck & Co., Inc. has an average rating of "Moderate Buy" and a consensus target price of $151.92.

Insider Transactions at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP Jennifer Zachary sold 80,315 shares of the company's stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the transaction, the executive vice president owned 45,509 shares in the company, valued at approximately $6,073,631.14. This represents a 63.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Richard R. Deluca sold 11,699 shares of the company's stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $131.63, for a total value of $1,539,939.37. Following the completion of the sale, the executive vice president owned 110,167 shares of the company's stock, valued at approximately $14,501,282.21. The trade was a 9.60% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 228,238 shares of company stock worth $29,977,783. 0.17% of the stock is owned by insiders.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reported promising skin-cancer trial results involving Keytruda and a personalized mRNA vaccine. Positive clinical data could strengthen confidence in Merck’s oncology franchise and support longer-term growth. Merck reports promising skin cancer trial results
• Positive Sentiment: Merck is scheduled to present first-time pivotal Phase 3 oncology results at ESMO 2026, including melanoma and endometrial-cancer programs, alongside an oncology investor event. The disclosures may demonstrate progress in replacing or extending revenue from existing cancer therapies. Merck ESMO 2026 oncology pipeline preview
• Positive Sentiment: Merck’s continued uptrend has encouraged options traders to consider bullish strategies, indicating that some market participants expect further gains. Options activity, however, can amplify volatility and does not by itself change the company’s fundamentals. Merck bullish options strategy
• Neutral Sentiment: Merck’s investment narrative has shifted toward oncology and other growth opportunities as investors look beyond challenges affecting Gardasil, particularly in China. The strategy could improve diversification, but execution and pipeline commercialization remain key.
• Neutral Sentiment: Merck is being compared favorably with other pharmaceutical companies on dividend sustainability and cash generation, though the articles do not identify a major new dividend announcement. Merck versus Amgen dividend comparison
• Negative Sentiment: After rising more than 38% in 2026, Merck trades at a substantially higher forward earnings multiple than in late 2025. Analysts warn that the market may already be pricing in significant pipeline success, leaving less room for upside and greater sensitivity to disappointing trial data. Merck valuation and rally analysis

Merck & Co., Inc. Stock Performance

MRK stock opened at $146.01 on Friday. Merck & Co., Inc. has a 1-year low of $82.01 and a 1-year high of $156.92. The stock has a 50-day moving average price of $145.60 and a 200-day moving average price of $129.24. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. The firm has a market cap of $360.22 billion, a PE ratio of 116.81, a price-to-earnings-growth ratio of 6.74 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.13. The business had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The company's revenue for the quarter was up 5.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities research analysts expect that Merck & Co., Inc. will post 2.66 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th were paid a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date was Tuesday, September 15th. Merck & Co., Inc.'s dividend payout ratio (DPR) is presently 272.00%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck's principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.